Outcomes following less-invasive-surfactant-administration in the delivery-room

Early Hum Dev. 2022 Apr:167:105562. doi: 10.1016/j.earlhumdev.2022.105562. Epub 2022 Feb 26.

Abstract

Background: Less invasive surfactant administration (LISA) on the neonatal unit reduces the need for mechanical ventilation and bronchopulmonary dysplasia (BPD).

Aims: To assess the immediate and longer-term efficacy of LISA to prematurely born infants in the delivery-room.

Study design: A case control study with inborn historical controls matched for gestational age, birthweight and gender to each LISA infant.

Subjects: Infants born between 26+0 weeks and 34+6 weeks of gestational age.

Outcome measures: Respiratory function monitoring before and after LISA and need for mechanical ventilation within 72 h of birth.

Results: Ninety-nine infants, median gestational age of 32+4(range:27+0-34+6) weeks, were prospectively recruited. The respiratory rate and inspired oxygen (FiO2) decreased two minutes after LISA and there was a reduction in the FiO2 requirement at two hours post birth. Compared to historical controls, LISA administration was associated with a reduction in the need for mechanical ventilation within 72 h after birth (20.2% versus 56.6% p < 0.001) the incidence of moderate to severe BPD (8.2% versus 20.2%, p = 0.02) and the median costs of neonatal intensive care stay (£1218 versus £2436, p = 0.03) and total neonatal unit stay (£12,888 versus £17,240, p = 0.04). A high FiO2 in the delivery-room pre-LISA (median 0.75 versus 0.60, p = 0.02) was associated with LISA failure, that is mechanical ventilation within 72 h of birth.

Conclusions: LISA to prematurely born infants in the delivery-room was associated with reductions in the need for mechanical ventilation and costs of care, but was less successful in those with initial, more severe respiratory disease.

Keywords: Healthcare cost; LISA; LISA failure; Respiratory function monitor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Continuous Positive Airway Pressure
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Intubation, Intratracheal
  • Respiration, Artificial
  • Respiratory Distress Syndrome, Newborn* / drug therapy
  • Respiratory Distress Syndrome, Newborn* / epidemiology
  • Surface-Active Agents*

Substances

  • Surface-Active Agents